Uncategorized

The Board of Directors of Nordic Nanovector ASA has decided to postpone the upcoming Annual General Meeting, which was originally scheduled for 26 April.

HUTCHMED Limited announces that it completed the rolling submission of a New Drug Application to the U.S. Food and Drug Administration for fruquintinib, its highly selective and potent oral inhibitor of VEGFR-1, -2 and -3, for the treatment of refractory metastatic colorectal cancer.

GenScript Biotech, the world’s leading biotech company, announces its annual results as of December 31, 2022.

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, announces the appointment of Khalil Barrage as Interim Chair of the Board.

CANbridge Pharmaceuticals, Inc., a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced financial results for the twelve months ended 2022 and corporate update.

Everest Medicines announced its financial results for the full year ended December 31, 2022, along with a corporate update.

Hansa Biopharma, “Hansa”, a pioneer in enzyme technology for rare immunological conditions, announced it has completed enrollment in its phase 2 study of imlifidase in Guillain-Barré Syndrome.

BioArctic AB’s partner Eisai announced the publication of additional detailed analyses from the phase 2b clinical study, evaluating the efficacy and safety of lecanemab for mild cognitive impairment due to Alzheimer’s disease and mild AD.

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays for the fully automated LUMIPULSE® G Systems.

Although telehealth use declined overall compared to the start of the COVID-19 pandemic, virtual visits still comprised the highest percentage of medical claim lines in 2021.